← Product Code [IYE](/submissions/RA/subpart-f%E2%80%94therapeutic-devices/IYE) · K092550 # TIGRT IVS (K092550) _Linatech, LLC · IYE · Dec 15, 2009 · Radiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/RA/subpart-f%E2%80%94therapeutic-devices/IYE/K092550 ## Device Facts - **Applicant:** Linatech, LLC - **Product Code:** [IYE](/submissions/RA/subpart-f%E2%80%94therapeutic-devices/IYE.md) - **Decision Date:** Dec 15, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 892.5050 - **Device Class:** Class 2 - **Review Panel:** Radiology - **Attributes:** Software as a Medical Device ## Indications for Use TiGRT IVS is intended to be used in conjunction with Linac and Digital Panel for analyzing the current patient position and calculating the patient positioning shift correction factor, as well as the treatment portal verification and record. ## Device Story TiGRT IVS is an image viewing system used in radiation therapy. It receives image data from a digital panel and linear accelerator (Linac). The system analyzes current patient position relative to the treatment plan, calculates necessary positioning shift correction factors, and performs treatment portal verification and record-keeping. It is intended for use by clinical staff in a radiation therapy setting. The output is used by clinicians to adjust patient positioning before or during treatment, ensuring accurate radiation delivery. The system supports DICOM 3/RT standards for data exchange and operates over TCP/IP networks. ## Clinical Evidence No clinical data provided; bench testing only. ## Technological Characteristics Software-based image viewing system. Operates on Windows XP, Vista, or 7. Connectivity via TCP/IP. Supports DICOM 3/RT standards. Functions as an analysis and record-keeping tool for radiation therapy positioning. ## Regulatory Identification A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories. ## Predicate Devices - ExacTrac ([K072046](/device/K072046.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K09255D # Summary of Safety and Effectiveness July 20, 2009 #### 1. Submitter's Information Common/Usual Name: Image Viewing System Proprietary Name: TiGRT IVS, TiGRT DEC 1 5 2009 : Applicant Name and Address: LinaTech, LLC 1294 Kifer Road, #705 Sunnyvale, CA 94086 Telephone: 408-733-2051 Fax: 408-733-2045 #### 2. Predicate Devices ExacTrac (K072046) #### 3. Classification This device is classified as a Class II device according to 21 CFR 892.5050. #### 4. Performance Standards No applicable standards have been established by FDA under section 514 of the Food, Drug and Cosmetic Act. {1}------------------------------------------------ ### 5. Intended Use and Device Description TiGRT IVS is intended to be used in conjunction with Linac and Digital Panel for analyzing the current patient position and calculating the patient positioning shift correction factor, as well as the treatment portal verification and record. The intended use is the same as the predicate device. #### 6. Biocompatibilitv No new issues of biocompatibility are raised with regard to this device. ## 7. Summary of Substantial Equivalence This device is similar in design and construction, and has the same intended use and performance characteristics to the predicate device. It utilizes materials that are already in use in other medical devices. No new issues of safety or effectiveness are introduced by using this device. {2}------------------------------------------------ ### Table 1: Comparison of TiGRT IVS Modified Device with Predicate Device : 上 . . | Characteristic | Current Modified
Device TIGRT IVS | Predicate Device
ExacTrac (K072046) | |---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Operating
System | Windows XP / Vista
/7 | Windows XP Professional | | Networking | TCP/IP | TCP/IP | | Intended Use | TiGRT IVS is
intended to be used
in conjunction with
Linac and Digital
Panel for analyzing
the current patient
position and
calculating the
patient positioning
shift correction
factor, as well as the
treatment portal
verification and
record. | The ExacTrac 3rd party system is
intended to be used in conjunction
with the MHI-TM2000 radiation
therapy linear accelerator system
manufactured by Mitsubishi Heavy
Industries, Ltd. ExacTrac 3rd Party
uses the images received from the
MHI-TM2000 linear accelerator for
analyzing the current patient position
and calculating - when applicable - a
necessary correction shift. The
correction shift is then exported to the
MHI-TM2000 linear accelerator.
The ExacTrac 3rd Party system uses
stereoscopic x-ray or cone beam CT
registration and optical tracking of
infrared reflective markers in order to
localize and correct the patient
position before and during treatment. | | Application(Use) | Patient tracking and
positioning,
Portal verification
and record, | Patient tracking and positioning,
Portal verification and record. | | DICOM | DICOM 3/RT | DICOM 3/RT | {3}------------------------------------------------ Image /page/3/Picture/0 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an emblem of an eagle. #### DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002 Jonathan Yao, Ph.D. President and CEO LinaTech LLC 1294 Kifer Road, Suite 705 SUNNYVALE CA 94086 DEC 1 5 2009 Re: K092550 Trade/Device Name: TiGRT IVS Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: October 30, 2009 Received: November 5, 2009 Dear Dr. Yao: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations; Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical {4}------------------------------------------------ Page 2 - device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm Sincerely yours, Janine M. Morris Janine M. Morris Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5}------------------------------------------------ Page 1 of 1 510(k) Number (if known): K092550 Device Name:_____TiGRT IVS_ #### Indications for Use: TiGRT IVS is intended to be used in conjunction with Linac and Digital Panel for analyzing the current patient position and calculating the patient positioning shift correction factor, as well as the treatment portal verification and record. #### (PLEASE DO NOT WRITE BELLOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Optional Format 3-10-98) Prescription Use ____________________________(Per 21 CFR 801.109) _ (Division Sign-Off) Division of Reproductive, Abdominal and Radiological Devices 510 (k) Number _ --- **Source:** [https://fda.innolitics.com/submissions/RA/subpart-f%E2%80%94therapeutic-devices/IYE/K092550](https://fda.innolitics.com/submissions/RA/subpart-f%E2%80%94therapeutic-devices/IYE/K092550) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com